TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Everest Medicines Ltd. ( (HK:1952) ) has provided an update.
Everest Medicines Ltd. has announced that its board of directors will meet on March 25, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s market positioning.
More about Everest Medicines Ltd.
Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products. The company operates primarily in the healthcare industry, targeting unmet medical needs in the Asian markets.
YTD Price Performance: -7.44%
Average Trading Volume: 5,599,413
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$14.63B
For a thorough assessment of 1952 stock, go to TipRanks’ Stock Analysis page.